Ticker: MRNA

Moderna

Pharma Healthcare Biotechnology

Price 54.07

Reco Sell Potential 39 Risk 76 Updated 2026-07-27

Official website

Forecast impact

positive

Target +23.9% target fill 80.7%

Reaction D5 pending · D10 pending fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-08-20

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.

Investment Profile

The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.

Category: Pharma Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-07-27

EPS (TTM) — earnings per share for the last 12 months, $: -8.15
Revenue QoQ — quarter-over-quarter revenue growth: -42.6%
EPS surprise: 60.9%
20d volatility: 4.4%

AI recommendation changes

Date	Before	After	Reason
2026-07-09	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-07-02	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-23	Hold	Sell	Weak fundamentals and high volatility raise significant risk.
2026-06-19	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-11	Hold	Sell	scenario_deterioration
2026-06-05	Sell	Hold	Weak fundamentals offset by recent price momentum.
2026-06-03	Hold	Sell	scenario_deterioration
2026-05-28	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-16	Hold	Sell	scenario_deterioration
2026-05-08	—	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-08	Hold	Hold	Компания Moderna демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и снижение выручки указывают на риски. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении.
2026-03-27	Sell	Hold	Компания Moderna демонстрирует сильный рост за последние 60 и 120 дней, однако отрицательный EPS и значительное снижение выручки в квартальном выражении указывают на риски. Рекомендуется удерживать акции до прояснения фи
2026-03-20	Hold	Sell	Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на финансовые проблемы. Текущая цена акций также значительно ниже недавних максимумов, что может свидетельствовать о дальнейшем падении
2026-02-08	Buy	Hold	Компания показывает сильный рост выручки и положительную динамику за последние 60 дней, что указывает на высокий потенциал. Однако отрицательный EPS и высокая волатильность требуют осторожности.
2026-01-30	Hold	Buy	Компания Moderna демонстрирует значительный рост выручки и положительную динамику акций за последние месяцы, что указывает на потенциал для дальнейшего роста. Однако отрицательный EPS и высокая волатильность требуют осто
2026-01-25	Buy	Hold	Компания Moderna демонстрирует сильный рост выручки и позитивные результаты по сюрпризам, однако отрицательный EPS и высокая волатильность акций указывают на значительные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-07-21	Goldman Sachs	Target Raised	49 → 67	59.49
2026-07-20	Wolfe Research	Target Raised	— → 25	61.82
2026-07-08	Morgan Stanley	Target Raised	33 → 39	79.77
2026-07-07	RBC Capital	Target Raised	38 → 45	81.8
2026-06-26	Piper Sandler	Target Raised	69 → 77	67.66
2026-05-04	UBS	Target Raised	36 → 45	47.465
2026-05-04	RBC Capital	Target Raised	35 → 38	46.87
2026-05-01	Goldman Sachs	Target Raised	43 → 49	45.37
2026-05-01	Morgan Stanley	Target Raised	30 → 33	44.18
2026-03-03	Jefferies	Update	— → 37	49.83
2026-02-17	RBC Capital	Target Raised	25 → 30	42.54
2026-02-17	Evercore ISI	Target Raised	28 → 35	43.19
2026-02-17	Bernstein	Target Raised	35 → 45	42.23
2026-02-16	UBS	Target Raised	34 → 36	42.23
2026-02-16	Morgan Stanley	Target Raised	28 → 30	42.23

News Page 1 of 1

Analysts Jim Cramer recommends waiting for a pullback before buying Moderna (MRNA) shares as the company unveils a promising cancer pipeline

07/01/2026, 04:36 PM business recommendation Analysts: analysts healthcare Moderna

Moderna is gaining renewed investor interest as it expands its pipeline beyond Covid-19 vaccines, with promising developments in cancer therapies and other vaccine programs. This shift could signal a potential turnaround for the company after a period of uncertainty.

Analysts Morgan Stanley recommend buying Microsoft (MSFT) shares despite recent declines

06/29/2026, 04:36 PM investing recommendation Analysts: analysts, Morgan Stanley software Microsoft Alphabet Constellation Brands NRG Energy Merck Bio-Techne Moderna Nike

Alphabet's recent inclusion in the Dow Industrials has generated significant market attention, while Nike continues to struggle with a substantial decline in its stock price, impacting investor sentiment.

Analysts expect market volatility as major stocks like Apple (AAPL) and Kroger (KR) report earnings amid fluctuating economic indicators

06/17/2026, 05:35 PM investing review Analysts: analysts consumer finance JPMorgan Chase Comcast Kroger CME Group Moderna Salesforce Apple Bank of America

The article highlights significant market movements and upcoming events that could influence stock prices, particularly focusing on major companies like Apple, Moderna, and Kroger, as well as broader market trends in energy and banking sectors.